索托拉西布治疗的晚期KRASG12C突变非小细胞肺癌患者循环肿瘤DNA的临床效用
该前瞻性生物标志物研究纳入66例接受索托拉西布治疗的KRASG12C突变非小细胞肺癌患者,治疗前可检出KRASG12C ctDNA者无进展生存期和总生存期均较差;首次疗效评估时29例(73%)达分子学缓解,分子学未缓解者总生存期较差,分子学缓解者疾病控制率显著更高;KRAS扩增为反复出现的获得性改变。
要点
- 治疗前可检出KRASG12C ctDNA与较差的无进展生存期(HR 2.13)和总生存期(HR 2.61)相关。
- 首次疗效评估时分子学未缓解者总生存期较差(HR 3.58)。
- KRAS扩增被识别为索托拉西布的潜在反复出现耐药机制。
核心结论
- 数据提示治疗前可检出的KRASG12C ctDNA是预后不良的标志,治疗中ctDNA清除是治疗反应的标志。
- KRAS扩增被识别为索托拉西布潜在反复出现的耐药机制。
- 识别预后较好的患者可能有助于优化治疗开始时机,识别有早期进展风险的患者可能有助于更早做出治疗决策。
研究设计与样本
- 前瞻性生物标志物研究(NCT05221372),纳入接受索托拉西布治疗的KRASG12C突变非小细胞肺癌患者。
- 在索托拉西布治疗前、首次疗效评估时和疾病进展时采集血浆样本。
- 采用TruSight Oncology 500 panel进行ctDNA和变异等位基因频率分析。
- 肿瘤反应和无进展生存期按实体瘤疗效评价标准1.1版评估。
主要发现
- 66例患者中50例(76%)治疗前可检出KRASG12C ctDNA。
- 可检出KRASG12C者无进展生存期较差(HR 2.13 [95%CI: 1.06-4.30],p=0.031),总生存期较差(HR 2.61 [95%CI: 1.16-5.91],p=0.017)。
- 首次疗效评估时(n=40),29例(73%)达分子学缓解。
- 分子学未缓解者总生存期较差(HR 3.58 [95%CI: 1.65-7.74],p=0.00059)。
- 分子学缓解者疾病控制率显著更高(97% vs 64%,p=0.015)。
关键数值与推荐
- 治疗前KRASG12C ctDNA可检出与不可检出相比,无进展生存期HR 2.13(95%CI: 1.06-4.30),p=0.031。
- 治疗前KRASG12C ctDNA可检出与不可检出相比,总生存期HR 2.61(95%CI: 1.16-5.91),p=0.017。
- 首次疗效评估时分子学未缓解与缓解相比,总生存期HR 3.58(95%CI: 1.65-7.74),p=0.00059。
- 分子学缓解者与未缓解者疾病控制率分别为97%与64%,p=0.015。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: For patients with KRASG12C-mutated NSCLC who are treated with sotorasib, there is a lack of biomarkers to guide treatment decisions. We therefore investigated the clinical utility of pretreatment and on-treatment circulating tumor DNA (ctDNA) and treatment-emergent alterations on disease progression. METHODS: Patients with KRASG12C-mutated NSCLC treated with sotorasib were prospectively enrolled in our biomarker study (NCT05221372). Plasma samples were collected before sotorasib treatment, at first-response evaluation and at disease progression. The TruSight Oncology 500 panel was used for ctDNA and variant allele frequency analysis. Tumor response and progression-free survival were assessed per Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS: Pretreatment KRASG12C ctDNA was detected in 50 of 66 patients (76%). Patients with detectable KRASG12C had inferior progression-free survival (hazard ratio [HR] 2.13 [95% confidence interval [CI]: 1.06-4.30], p = 0.031) and overall survival (HR 2.61 [95% CI: 1.16-5.91], p = 0.017). At first-response evaluation (n = 40), 29 patients (73%) had a molecular response. Molecular nonresponders had inferior overall survival (HR 3.58 [95% CI: 1.65-7.74], p = 0.00059). The disease control rate was significantly higher in those with a molecular response (97% versus 64%, p = 0.015). KRAS amplifications were identified as recurrent treatment-emergent alterations. CONCLUSIONS: Our data suggest detectable pretreatment KRASG12C ctDNA as a marker for poor prognosis and on-treatment ctDNA clearance as a marker for treatment response. We identified KRAS amplifications as a potential recurring resistance mechanism to sotorasib. Identifying patients with superior prognosis could aid in optimizing time of treatment initiation, and identifying patients at risk of early progression could allow for earlier treatment decisions.
引用
- Ernst SM, van Marion R, Atmodimedjo PN, et al. Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib. J Thorac Oncol. 2024. PMID: 38615940. doi:10.1016/j.jtho.2024.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。